ESSA Total Current Liabilities from 2010 to 2024
| EPIX Stock | USD 6.20 0.04 0.64% |
Total Current Liabilities | First Reported 2013-09-30 | Previous Quarter 3.5 M | Current Value 4.2 M | Quarterly Volatility 2 M |
Check ESSA Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ESSA main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 5.9 K or Selling General Administrative of 7.6 M, as well as many exotic indicators such as Price To Sales Ratio of 272.8 K, Dividend Yield of 0.0 or PTB Ratio of 0.88. ESSA financial statements analysis is a perfect complement when working with ESSA Pharma Valuation or Volatility modules.
ESSA | Total Current Liabilities |
Latest ESSA Pharma's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of ESSA Pharma over the last few years. Total Current Liabilities is an item on ESSA Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ESSA Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. ESSA Pharma's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ESSA Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
ESSA Total Current Liabilities Regression Statistics
| Arithmetic Mean | 2,692,449 | |
| Geometric Mean | 1,764,113 | |
| Coefficient Of Variation | 60.17 | |
| Mean Deviation | 1,317,011 | |
| Median | 3,273,679 | |
| Standard Deviation | 1,619,958 | |
| Sample Variance | 2.6T | |
| Range | 5.4M | |
| R-Value | 0.60 | |
| Mean Square Error | 1.8T | |
| R-Squared | 0.36 | |
| Significance | 0.02 | |
| Slope | 218,433 | |
| Total Sum of Squares | 36.7T |
ESSA Total Current Liabilities History
About ESSA Pharma Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include ESSA Pharma income statement, its balance sheet, and the statement of cash flows. ESSA Pharma investors use historical funamental indicators, such as ESSA Pharma's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although ESSA Pharma investors may use each financial statement separately, they are all related. The changes in ESSA Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ESSA Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ESSA Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ESSA Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 4 M | 3.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ESSA Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ESSA Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Essa Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Essa Pharma Stock:Check out the analysis of ESSA Pharma Correlation against competitors. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for ESSA Stock analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |
Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.14) | Return On Equity (0.19) |
The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.